News & Updates

Treatment with risankizumab (RZB) results in significantly lower absolute Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores at week 52 in bio-naïve psoriasis patients compared with other biologic therapies, according to the results of a 2-year interim analysis from the German cohort of the VALUE study, presented at EADV 2023.

Twice-daily application of the botanical coacillium 22.25% cutaneous solution leads to significant hair growth in children and adolescents with moderate-to-severe alopecia areata (AA), with the improvement in hair loss sustained through months after treatment discontinuation, according to data from the phase II/III RAAINBOW trial.

The monovalent mRNA vaccine helped stave off severe COVID-19 outcomes in children aged 1 to 4 years during the Omicron wave, as shown in a study from Singapore.

Ischaemic stroke (IS) patients with consistently controlled blood pressure (BP) and who regularly take antihypertensive medications following discharge have lower risks of death and vascular events, reports a recent study.

The experimental drug amlitelimab has scored positive outcomes in the double-blind, placebo-controlled phase IIb STREAM-AD study evaluating it as a treatment for moderate-to-severe atopic dermatitis (AD).

Frequent use of alpha-1 receptor blockers is neither harmful nor protective against the risk of uncomplicated or severe COVID-19 hospitalization, a study has shown.

In children and adults with moderate-to-severe atopic dermatitis, applying tapinarof cream 1% helps reduce itch within 24 hours, according to the results of the phase III trials ADORING 1 and 2.